File downloaded on 2026-11-03
**Source URL:** https://medicines.health.europa.eu/veterinary/en/600001882810

# Nobivac NXT HCP (--) - Lyophilisate and solvent for suspension for injection

Authorised

- Feline panleucopenia virus, strain MW-1, Live
- Feline calicivirus, strain F9, Live
- Felid herpesvirus 1, strain G2620A, Live

## Product identification

**Medicine name:**
Nobivac NXT HCP (--) - Lyophilisate and solvent for suspension for injection

**Active substance:**
Feline panleucopenia virus, strain MW-1, Live

Feline calicivirus, strain F9, Live

Felid herpesvirus 1, strain G2620A, Live

**Target species:**
Cat

**Route of administration:**
Subcutaneous use

## Product details

**Active substance and strength:**

Feline panleucopenia virus, strain MW-1, Live

Presentation_strength:$10^{5.2}$ – $10^{6.4}$ $TCID_{50}$ Index:2

Feline calicivirus, strain F9, Live

Presentation_strength:$10^{4.6}$ – $10^{7.0}$ PFU Index:1

Felid herpesvirus 1, strain G2620A, Live

Presentation_strength:$10^{5.8}$ – $10^{7.1}$ PFU Index:0

**Pharmaceutical form:**

Lyophilisate and solvent for suspension for injection

**Anatomical therapeutic chemical veterinary (ATCvet) codes:**

QI06AD04

**Legal status of supply:**

Veterinary medicinal product subject to veterinary prescription

**Authorisation status:**

Valid

**Authorised in:**

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

**Package description:**

Packaging:Vial (Type I clear glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 1 dose + solvent: 0.5 ml

Packaging:Vial (Type I clear glass), Package_size:Lyophilisate: 25 vials + solvent: 25 vials, Content:Lyophilisate: 1 dose + solvent: 0.5 ml

## Additional information

**Entitlement type:**

Marketing Authorisation

**Legal basis of product authorisation:**

Full application - known active substance (Article 8 of Regulation (EU) 2019/6)

**Marketing authorisation holder:**
Intervet International B.V.

**Marketing authorisation date:**
2/07/2026

**Manufacturing sites for batch release:**
Intervet International B.V.

**Responsible authority:**
European Commission

**Authorisation number:**
This information is not available for this product.

**Date of authorisation status change:**
2/07/2026

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

## Documents

Combined File of all Documents

English (PDF)
Published on: 10/07/2026
Download

ema-puar-v6681-nobivacnxthcp-initial-en.pdf